Clinical trials: Stage III Non-Small Cell Lung Cancer AJCC v7
Non Small Cell Lung Cancer
Multicenter Phase 2 Trial Evaluating Cisplatin-Gemcitabine With Concomitant Thoracic Radiotherapy for Treatment of Inoperable Stage III Non Small Cell Lung Cancer
The purpose of the study is to evaluate the response rate of patients with non small lung cancer to gemcitabine in combination with radiotherapy. The tolerability and safety of this combination will also be evaluated.
- Trial name
- NCT00192036
- Testing
- gemcitabine, cisplatin, radiation
- Where
- 8 sites in Belgium
- Volunteers
- 49 people
- Sponsor
- Eli Lilly and Company
Vinorelbine
Efficacy and Safety of Concurrent Chemoradiotherapy With Oral Vinorelbine in Patients With Non-small Cell Lung Cancer
To evaluate the efficacy and safety of concurrent chemoradiotherapy with oral vinorelbine, and immune maintenance therapy in patients with unresectable stage III non-small cell lung cancer after neoadjuvant chemo-immunotherapy…
- Trial name
- NCT06540950
- Testing
- vinorelbine
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Stage III Non-small Cell Lung Cancer
Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial
For stage III non-small cell lung cancer (NSCLC), neoadjuvant chemotherapy plus PD-1 antibody is recommended. However, most patients could not achieve complete pathological response (CPR).
- Trial name
- NCT05891080
- Testing
- Toripalimab, JS004, Pemetrexed
- Volunteers
- 124 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Lung Cancer
S0429: Docetaxel, Cetuximab, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00288054
- Testing
- cetuximab, docetaxel, radiation therapy
- Where
- 77 sites in United States
- Volunteers
- 24 people
- Sponsor
- SWOG Cancer Research Network
Lung Cancer
Cisplatin, Vinorelbine, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as cisplatin and vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- SOCCAR (NCT00309972)
- Testing
- Control arm (SEQ):, Experimental arm (CON):
- Where
- United Kingdom
- Volunteers
- 130 people
- Sponsor
- University College, London
Lung Cancer
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00004093
- Testing
- carboplatin, Gemcitabine, paclitaxel
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Northwestern University
Non-small Cell Lung Cancer Stage III
A Study of Envafolimab in Subjects With Stage III Non-Small Cell Lung Cancer
This is a prospective, single arm, phase II study to evaluate the efficacy and safety of Envafolimab in subjects with locally advanced/unresectable (Stage III) non-small cell lung cancer that has not progressed after prior…
- Trial name
- NCT05414630
- Testing
- Envafolimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Anhui Provincial Cancer Hospital
NSCLC
Significance of MRD Monitoring in Patients With Potentially Resectable Stage III Non-small Cell Lung Cancer
Stratification of postoperative ctDNA status can effectively assess the risk of recurrence in patients. In addition, the multi-node dynamic monitoring of ctDNA is more effective in predicting the recurrence risk of patients.
- Trial name
- MRDinS3LC (NCT06081777)
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Peking University Cancer Hospital & Institute
Carcinoma, Non-Small-Cell Lung, Non-small Cell Lung Cancer
Erlotinib or Placebo Following Chemoradiotherapy (Chemo/RT) in Stage III Non-Small Cell Lung Cancer (NSCLC)
This is a national, randomized, web-based, double-blind study to determine whether erlotinib (Tarceva) compared to placebo improves progression-free survival (PFS) for patients with inoperable, stage III NSCLC following…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Non-small Cell Lung Cancer, NSCLC
- Trial name
- NCT00153803
- Testing
- Erlotinib (tarceva)
- Where
- 65 sites in United States
- Volunteers
- 245 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Non-Small Cell Lung Cancer
Phase II Iressa + Irradiation Followed by Chemo in NSCLC
The objective of this study is to determine wether the ZD1839 associated with a radiotherapy, before the beginning of chemotherapy is effective in the treatment of your disease and to evaluate the tolerance of these treatments.
- Trial name
- NCT00333294
- Testing
- Gefitinib, Radiation therapy, Cisplatin
- Where
- 4 sites in France
- Volunteers
- 50 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer
Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung Cancer
Sorafenib has demonstrated in vivo anti-tumor efficacy. This trial will evaluate the safety and preliminary efficacy of sorafenib following chemoradiation in locally advanced NSCLC.
- Trial name
- NCT00417248
- Testing
- Cisplatin, Etoposide, Radiotherapy
- Where
- 8 sites in United States
- Volunteers
- 8 people
- Sponsor
- Nasser Hanna, M.D.
Lung Cancer
Vandetanib, Carboplatin, and Paclitaxel in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed by Surgery
RATIONALE: Vandetanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00459121
- Testing
- carboplatin, paclitaxel, Zactima
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Recurrent Lung Non-Small Cell Carcinoma, Stage II Non-Small Cell Lung Cancer AJCC v7
Image-Guided, Intensity-Modulated Photon or Proton Beam Radiation Therapy in Treating Patients With Stage II-IIIB Non-small Cell Lung Cancer
This partially randomized phase I/II trial studies the side effects and best dose of image-guided, intensity-modulated photon or proton beam radiation therapy and to see how well they work in treating patients with stage II-IIIB…
- Conditions
- Recurrent Lung Non-Small Cell Carcinoma, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7
- Trial name
- NCT01629498
- Testing
- Image Guided Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 146 people
- Sponsor
- M.D. Anderson Cancer Center
Locally-Advanced Non-Small Cell Lung Cancer, Radiotherapy
Centrally Confined 8Gy/1f to Tumor Core Followed by Concurrent Chemoradiotherapy for Unresectable Stage III NSCLC
This is a single-center, prospective, open-label, single-arm phase I exploratory study designed to evaluate the safety and feasibility of a novel central immune-priming radiotherapy strategy in patients with unresectable stage…
- Trial name
- NCT07523464
- Testing
- Centrally Confined 8 Gy/1 Fraction Immune-Priming Radiotherapy to the Tumor Core Followed by Definitive Concurrent Chemoradiotherapy
- Volunteers
- 24 people
- Sponsor
- Anhui Provincial Hospital
Non Small Cell Lung Carcinoma
Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC
The aim of the study if to determine if Iressa can prolong the period of time without any disease worsening (Time to progression) in patients previously treated with combined therapy such as surgery and chemotherapy with or…
- Trial name
- NCT00234468
- Testing
- Iressa (Gefitinib)
- Where
- 32 sites in Italy
- Volunteers
- 490 people
- Sponsor
- AstraZeneca
Non-small Cell Lung Cancer
Icotinib With Concurrent Radiotherapy vs. Chemoradiotherapy in Non-small Cell Lung Cancer
The current standard of care for unresectable locally advanced non-small-cell lung cancer (NSCLC) is a combination of chemotherapy and thoracic radiotherapy (TRT).
- Trial name
- NCT02407366
- Testing
- Icotinib, Pemetrexed, Carboplatin
- Where
- China
- Volunteers
- 80 people
- Sponsor
- People's Hospital of Guangxi Zhuang Autonomous Region
Stage III NSCLC
Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer
The use of neoadjuvant immuno-chemotherapy could improve survival outcomes of patients eligible for sequential radio-chemotherapy comparing to the benefit already obtained with maintenance immunotherapy.
- Trial name
- SPORADIC (NCT06656598)
- Testing
- Carboplatin, Paclitaxel, Cemiplimab
- Where
- 25 sites in France
- Volunteers
- 152 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer
Neoadjuvant Toripalimab Plus Platinum-based Doublet for Stage III Non-small Cell Lung Cancer
This is an open-label, single-arm, phase II, multi-center clinical trial. Thirty patients will be enrolled in this trial to investigate the pathological complete response rate defined as the absence of residual tumor in lung and…
- Trial name
- NeoTAP01 (NCT04304248)
- Testing
- Albumin-bound paclitaxel, Carboplatin, Toripalimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Hao Long
Lung Cancer
Radiation Therapy With or Without Vinorelbine and Cisplatin in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as vinorelbine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by…
- Trial name
- NCT00253591
- Testing
- cisplatin, vinorelbine tartrate, radiation therapy
- Where
- 20 sites in United Kingdom
- Volunteers
- 500 people
- Sponsor
- Medical Research Council
Non-Small Cell Lung Cancer
A Study of Dasatinib With Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to evaluate if a maximum dose of 100 mg of dasatinib with concurrent chemoradiation can be tolerated in patients with chemotherapy naive stage III NSCLC in separate cohorts of locally advanced and…
- Trial name
- NCT00787852
- Testing
- Group 1: Radiation, Paclitaxel,Carbo, Dasatinib days 1-47, Group 2: Radiation, Paclitaxel, Carbo, Dasatinib days 1-38
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Brown University